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Given that there may well be no significant advances in drug development before 2025, 
prevention of dementia/AD through the management of vascular and lifestyle-related risk 
factors may be a more realistic goal than treatment. Level of education and cognitive reserve 
assessment in neuropsychological testing deserve attention, as well as cultural, social and 
economic aspects of caregiving. Assistive technologies for dementia care remain complex. 
Serious games are emerging as virtual educational and pleasurable tools, designed for 
individual and cooperative skill-building. Public policies are likely to pursue improving 
awareness and understanding of dementia; providing good quality early diagnosis and 
intervention for all; improving quality of care from diagnosis to the end of life, using clinical 
and economic endpoints; delivering dementia strategies quicker, with an impact on more 
people. Dementia should remain presented as a stand-alone concept, distinct from frailty or 
loss of autonomy. The basic science of sensory impairment and social engagement in people 
with dementia needs to be developed. E-learning and serious games programmes may 
enhance public and professional education. Faced with funding shortage, new professional 
dynamics and economic models may emerge through coordinated, flexible research networks. 
Psychosocial research could be viewed as an investment in quality of care, rather than an 
academic achievement in a few centres of excellence. This would help provide a competitive 
advantage to the best operators. Stemming from care needs, a logical, systems approach to 
dementia care environment through organizational, architectural and psychosocial 
interventions may be developed, to help reduce symptoms in people with dementia and 
enhance quality of life. Dementia-friendly environments, culture and domesticity are key 
factors for such interventions. 
 






The Fondation Médéric Alzheimer initiated in 2007 a reflection on its future work on 
Alzheimer’s disease (AD) and related disorders. The objective was to develop an original, 
up-to-date, robust and valid conceptual framework on how the future context of dementia 
may unfold, engaging with uncertainty within limits of scientific plausibility (Brodaty et al., 
2011). The present article provides a synthesis of two international expert group meetings 
organized by the Fondation Médéric Alzheimer to delineate what is known, what is unknown 
and what may be plausible directions for the future. It is intended for a broad public: people 
with dementia and their families, dementia care professionals, policy-makers. This scientific 
outlook builds on experience gained from recent national policies in Europe. Furthermore, 
whenever possible, experts identified observable events of today that may become seeds of 
change for tomorrow. The future horizon has been set at 2025.  
 
Disease scope 
AD and related diseases differ from neurologic pathologies affecting mostly motor and 
sensory functions, and from non-degenerative pathologies affecting the mental sphere. AD is 
clearly and significantly different from normal ageing: it is a pathological process, which can 
be observed in structural and metabolic brain imaging. However, neuroimaging can also 
show biomarkers of AD in cognitively healthy people. These cases are currently designated 
as asymptomatic stage of the disease; a pathological evolution may be observable if these 
people live long enough and do not compensate for the disease. At the individual level, it is 
very difficult to disentangle normal aging from the early cognitive impairment of dementia, 
especially in advanced age (85+ years). Frailty, for its part, refers to a state of vulnerability, 
reflecting multi-system physiological and cognitive changes, which may evolve into impaired 
abilities to perform daily life activities. Cognitive and functional frailty coexist, depending 
upon the capacities of the cognitively impaired persons and their living ecosystem. Therefore, 
a disability model, which considers impairments in body functions and structures, limitations 
in individual activity and restrictions in social participation, is useful (World Health 
Organization, 2002). It is important to discuss preserving the person’s capacities rather than 
the sole biological aspects of the disease.  
 
Epidemiology, risk factors and prevention of dementia 
Prevalence of dementia will continue to rise worldwide as a consequence of demographic 
evolution, even if age-specific trend seems to be lower than previously expected (Larson, 
Yaffe & Langa, 2013). There are no data for prevalence, incidence and life expectancy using 
the new criteria for AD definition (Norton, Matthews, Barnes, Yaffe & Brayne, 2014). 
Natural history of this “extended” AD, partially studied through the control arms of clinical 
trials, is largely unknown. Many protective factors have been consistently found from large 
observational studies. Up to a third of AD cases worldwide are attributable to risk factors and 
could thus be prevented (Norton et al, 2014). Several epidemiology teams have shifted from 
observation to prevention intervention studies, based on the management of vascular and 
lifestyle-related risk factors. However, multiple individual and collective barriers to lifestyle 
change make prevention interventions very difficult. Data on efficacy of large ongoing 
preventive trials and adherence of elders in long-term prevention strategies are awaited to 
clarify whether reduction or removal of risk factors can substantially decrease AD or 
dementia incidence. Observable seeds for change include a large cooperation in the field of 
prevention across countries (European Dementia Prevention Initiative) (Mangialasche, 
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Kivipelto, Solomon & Fratiglioni, 2012). Useful measures at a State level would be to 
implement effective policies for individual and collective prevention, as well as policies 
towards agro-business companies and health insurance to change consumer behaviours such 
as those towards lipid-rich food (Gittelsohn & Lee, 2013). 
 
Understanding of cognitive ageing and dementia 
Understanding the complexity of dementia causation remains a major endeavor.  Dementia is 
not a simple disease, rather a syndrome (a set of signs and symptoms) with multiple 
interacting aetiologies (causes and factors), which can be clearly distinguished from normal 
ageing. Most preserved regions in normal aging are the hippocampus and posterior/cingulate 
regions (involved in strategic processes and episodic memory) which are part of the core 
process in AD pathology (Desgranges, Kalpouzos & Eustache, 2008). AD is not a myth: it 
can be considered as a structural problem (specific atrophy with a decrease of synaptic 
connections in regions of the brain) coupled with a fall in cerebral metabolism. Vascular 
determinants of AD became a key issue, with new links between metabolic and vascular 
pathways being unveiled. The role of exercise, education and cognitive reserve (brain 
capacity to offset cognitive impairments) in the prevention of dementia will need further 
investigation. The role of different risk and protective factors can be clarified by ongoing 
epidemiological studies, using a life-course perspective to describe the complex and dynamic 
interactions between factors in determining age-associated neurodegeneration.  
 
Biological causes of AD and dementia 
We remain almost entirely ignorant about the molecular mechanisms of AD and dementia. 
Since 2010, new insights emerged from molecular biology, but biological determinants of 
AD and dementia appear now more complex.  Both tau and amyloid pathologies are relevant 
for AD, but links between them are still ill-defined. Anatomically, tau-induced neurofibrillary 
degeneration is now well-described (Braak stages), with a very reproducible and specific 
sequence (Braak & Del Tredici, 2012), as opposed to the distribution of amyloid burden. 
There is a huge overlap among neurodegenerative disorders, with common mechanisms such 
as a prion-like propagation and mixed pathologies (AD and vascular dementia). Better cross-
linking of animal and human studies in neurodegenerative diseases should be encouraged.  
Although genome-wide association studies (GWAS) identified a number of new 
susceptibility genes in people with AD, the exact role of these genes in complex biological 
regulation pathways remains elusive.  
 
Detection and diagnosis of dementia 
While the new Diagnostic and Statistical Manual of Mental Disorders (DSM-5) abandoned 
the word of dementia to propose major (and mild) neurocognitive disorders as new diagnostic 
categories, the concept of dementia remains widely used. Complete clinical 
neuropsychological assessment (comprehensive cognitive evaluation) remains today the only 
way to make an accurate diagnosis of early cognitive disorder in AD or other dementia. 
Cognitive testing is included in memory clinics and in research, but not sufficiently in 
professional practice in nursing homes. Underlying causes of memory disorders appear 
heterogeneous and sometimes difficult to determine, challenging predictions of individual 
disease course. In France, 25% of diagnoses in memory centres remain pending (Le Duff et 
al, 2012). On another hand, neuroimaging techniques and research for diagnosis biomarkers 
developed rapidly in the past decade. Apart from cerebro-spinal fluid (CSF) amyloid, and 
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positron emission tomography (PET) cerebral amyloid imaging, biomarkers reflect different 
pathological processes that may occur at different times of the disease evolution, with a 
variable importance between patients, and in different combinations. In patients with mild 
cognitive impairment, CSF amyloid is a predictive marker of AD, but atrophy seen in 
magnetic resonance imaging (MRI) is a slightly better predictor of the rate of clinical decline. 
Task-free (resting) MRI and task-based MRI may prove useful as non-invasive biomarkers in 
studying the progression of memory failure over the course of AD. However, despite 
neuroimaging progress in biomarkers, their predictive power is not high enough to allow their 
use in screening. Blood biomarkers remain elusive. As a consequence, biomarkers are still 
reserved to research. It may still be so in the next ten years. Studies on biomarker validation 
will provide researchers with a better understanding of AD progression, in order to detect 
which systems are affected in its earliest stages. A better understanding of the underlying 
causes of dementia may eventually lead to more personalized therapeutic interventions, and 
in the development of new treatments that may modify the course of the disease. From the 
regulatory viewpoint, biomarker use became an important issue, to enrich the population 
recruited in randomized clinical trials in people with AD or other causes of cognitive decline. 
As early diagnosis may be of interest for earlier clinical trials, prognostic markers may 
eventually prove more useful than diagnostic ones. An early and timely diagnosis is 
important to facilitate adjustment of people and their family to living with the disease, and to 
adapt care modalities (Brooker, La Fontaine, Evans, Bray & Saad, 2013).  
 
New therapeutic targets for AD 
A drug able to stop or reverse AD progression (i.e., disease-modifying drug) is not yet 
available. Between 2002 and 2012, 99.6% of the 244 agents tested for efficacy in slowing the 
progression of AD failed to achieve their primary clinical endpoints (Ousset et al, 2014). The 
aetiology and pathophysiology of AD are not fully known, making it difficult to identify a 
proper target and develop an effective cure. We do not know when a disease-modifying drug 
for AD will be available. A different methodological approach is now being implemented to 
test anti-amyloid drugs, based on earlier intervention (at pre-symptomatic phase). This is 
done through the selection of subjects with genetic risk of familial AD or evidence of brain 
amyloid burden. New therapeutic approaches are being considered, including compounds 
regulating brain response to insulin and neuroinflammation. However, since AD is not a pure 
entity, better prevention appears more valuable than finding too many molecular targets for 
therapy.  
 
Psychosocial research and interventions in dementia 
More and more well conducted randomized studies show durable effect of psychosocial 
interventions (e.g. cognitive stimulation, music or art-therapy workshops)(Guétin et al, 2009), 
which have been shown to be effective in managing functional, behavioral and psychological 
symptoms of dementia. Basic processes involved in psychosocial interventions should be 
identified better (Cohen-Mansfield, Marx, Thein & Dakheel-Ali, 2011). New methodological 
approaches associating quantitative and qualitative evaluation should be encouraged. 
Psychosocial research may explore whether psychosocial interventions, along or without 
psychiatric medication, enhance or not each other’s impact. Cultural, social and economic 
aspects of caregiving deserve more attention. Protective factors, such as education and 
cognitive reserve, should be given more consideration in neuropsychology assessment and 
psychosocial interventions. Increased collaborative contracting is needed between 
neuropsychological research and clinical teams (particularly in nursing homes) in order to 
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develop clinical trials together. Multicomponent non-pharmacological interventions, 
comprising information to caregivers or cognitive approach to facilitate daily activities of 
people with dementia, are effective, although their evaluation is complex (Brodaty & 
Arasaratnam, 2012). Psychosocial intervention at home can be beneficial in reducing 
behavioral symptoms, when individually tailored and when applied during a sufficient period. 
Research is needed to understand the most efficient procedures for psychosocial intervention, 
their mechanisms of efficacy and the modulating factors. Early psychosocial intervention at 
home should be developed, based on an individual model of patients’ needs. Stimulation 
approaches should be expanded to match the full range of cognitive and sensory impairments.  
 
Assistive technology and dementia 
Information and Communication Technologies (ICTs) can provide useful information for 
assisting older adults and also for assessing specific domains of AD patient’s life (behaviour, 
cognition, functional status). Assistive technology must be specifically tailored to the end-
user’s capacities. Reliability of these ICTs is hard to achieve. Several initiatives have been 
organized to establish recommendations for ICT use in AD (Robert et al., 2013). Some 
clinical studies on long duration have shown the difficulties in identifying strong benefits of 
using ICTs for people with AD. More efforts in performance and evaluation of ICTs are 
needed to help industry meet user needs and general practitioners in prescribing the available 
technologies. A solid economic model is a major issue: who will pay for assistive 
technology? Who will install and maintain ICTs at AD patients’ homes? The cost–
effectiveness balance for assistive technology remains a matter of debate. Serious games, 
adapted to people with dementia, may constitute an important tool to maintain autonomy 
(Robert et al., 2014). By providing pleasurable activities and person empowerment, these 
games are a way to enter the homes of people with dementia through technology, to structure 
collaborative care knowledge related to AD and to educate AD stakeholders cope with 
critical situations in patient everyday life. Establishing links between behavioural disorders 
and their causes could help a personal or virtual coach in proposing corrective actions and 
lifestyle training. The role of technology in improving sensory impairments, facilitating 
activities of daily living and providing pleasure is under-explored. 
 
Sensory impairment and dementia 
The relation between sensory impairment and dementia is under-studied. Sensory 
impairments may be either causal factors or consequences of dementia. Whether sensory 
impairments could be markers or modifiable risk factors for dementia remains debated. A 
double disability approach (dementia and sensory impairment) may bring new insight 
(McKeefry D. & Bartlett R., 2010). Olfaction disorders as predictors of cognitive impairment 
remain a debated topic. Low vision is significantly associated to the development of 
dementia. People with a good or excellent vision may have a risk reduced by 37% to develop 
dementia within 8.5 years. People with a poorer vision who do not visit an ophthalmologist 
may have a 9.5-fold increased risk of AD and a 5-fold increased risk of cognitive impairment 
without dementia (Rogers & Langa, 2010). Hearing loss is associated with an increased risk 
of incident dementia: 2-fold for mild, 3-fold for moderate and 5-fold for severe hearing loss 
(Lin et al., 2011).  Non-corrected hearing loss with social discomfort is often confused with 
cognitive impairment, as people may fail to understand some high-pitch consonants or entire 
words in the questions of cognitive tests. People with dementia and delusions have also 
poorer vision and hearing. However, delusions may not represent psychotic symptoms: their 
true meaning may be related to disorientation, representation of reality, re-experience of past 
7 
 
events, loneliness, insecurity, boredom, or other triggering events (Cohen-Mansfield, 
Golander, Ben-Israel & Garfinkel, 2011). Delirium, an acute failure of the brain's ability to 
assimilate and respond appropriately to inner and outer stimuli, appears as a very strong risk 
factor for dementia in the oldest-old population (Davis et al, 2012), increasing dementia 
incidence by a factor of 9, and dementia severity or global function by a factor of 3. Proper 
identification of underlying causes, a suitable care environment and reorientation of the 
person may decrease adverse outcomes of delirium.  
 
Biomedical ethics and dementia 
A person-centred approach is essential for the well-being of people with dementia (Alzheimer 
Society of Canada, 2011). Challenging the stigma associated with dementia and promoting 
initiatives enabling people with dementia and their families to live well in the community is 
also of great importance (Van Gorp & Vercruysse, 2011). Assessment of decision-making 
capacity (e.g. to consent to treatment or research, to appoint a proxy, to vote) has emerged as 
a new area of practice and research, with a shift from a diagnosis-based approach to the 
consideration of key functional abilities. New criteria and tools for AD diagnosis create an 
opportunity for an earlier diagnosis, which holds great interest for clinical research but which 
may be ethically sensitive if translated in clinical practice. Considering AD and dementia 
through the framework of the disability model creates an opportunity to understand better the 
importance of psychosocial interventions and of societal changes aimed at social 
participation. Some ethical issues have not yet received as much attention as one might have 
expected: research in nursing homes, clinical trials for complex cases and effects of cultural 
differences on attitudes and practices about dementia. The ethics of assistive technology has 
been discussed in general terms, but a framework to analyze the ethical issues related to the 
use of a particular technology in a given context is still missing. Communication about AD 
research (funding and results) deserves more care, as it can reinforce stigma and give 
unrealistic hopes (Gzil, 2013). 
 
Care for people with dementia 
Dementia care involves multiple domains: functional, cognitive and intellectual, emotional, 
medical (including pain management), and end-of-life care. Behavioural and psychological 
symptoms of dementia (BPSD) are extremely important in explaining the burden of the 
disease for the persons themselves, caregivers and society. BPSD relate to unmet needs of 
people with dementia, mostly pain and discomfort, need of social contact and support, and 
need of stimulation against boredom (Cohen-Mansfield, 2013a). There is evidence that 
agitated behavior responds to pain management (Husebo, Ballard, Cohen-Mansfield, Seifert 
& Aarsland, 2014). Although non-pharmacological interventions are recommended as first-
line therapy for BPSD, a number of barriers to their delivery have been observed, which may 
be related to the people with dementia, staff, families, environment or systems processes 
(Cohen-Mansfield, Thein & Marx, 2014). Stemming from care needs, a logical, systems 
approach of the care environment through organizational, architectural and psychosocial 
interventions needs therefore to be developed. Future of psychosocial interventions may 
include the notion of “successful dementia” (Cohen-Mansfield et al, 2013b) to prevent 
negative affect and agitation while maximizing indications of positive affect, such as 
contentment and pleasure (Cohen-Mansfield, 2011). This involves a shared understanding of 
non-pharmacological intervention on communication and teamwork in care services; 
enhancing a multidisciplinary approach that would allow for the tailoring and 
individualization that is required of successful interventions; the integration of clinical 
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research and systems (organizational) research; research in nursing homes and research in 
individual homes. Dementia-friendly environments, culture (collective habits, values and 
beliefs acquired in human societies) and domesticity are key factors for such interventions. A 
new dynamics of research might evolve through coordinated, flexible research networks, 
involving field and university professionals; research in dementia care could become a 
marker of quality for innovative nursing homes. 
 
Public policies, economics and dementia 
Early diagnosis and early intervention should be a priority in public policy, to help organize 
the care pathway, to enable people with dementia and their families to make their own 
choices and to prevent the harms that accrue from not knowing what is going on. Policy 
focuses on spending now to save in the long term. Diagnosis and treatment became a right. 
Direct measurements of cost and effectiveness of interventions are scarce. Programmes, 
strategies and initiatives must be evaluated on a qualitative and quantitative basis, to assess 
reproducibility in different settings. The best models of care are poorly diffused and 
implemented. The number of countries having implemented a National Dementia Strategy is 
expanding gradually. Recently, WHO and the G8 countries have given dementia a status of 
public health priority, raising policy attention worldwide. Dementia is very expensive, with 
high costs stemming from the cost of care. Many services, such as care homes, offer poor 
value for money. There is a need for a better understanding of the cost drivers, as well as 
dementia and ageing as a macro-economic issue. We have no comprehensive models for 
dementia costs over time. The cost of inaction (not doing anything) should be integrated into 
the costing model, to remove perverse incentives. Further developments in the economics of 
dementia may increase political will and focus. Public policies are likely to pursue improving 
awareness and understanding of dementia; providing good quality early diagnosis and 
intervention for all; improving quality of care from diagnosis to the end of life, using clinical 
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Table 1: What is known? 




AD and related diseases differ from healthy ageing, from 
neurologic pathologies affecting mostly motor and sensory 
functions, and from non-degenerative pathologies 
affecting the mental sphere. 
 
Epidemiology, risk factors 
and prevention 
 
Prevalence of dementia will continue to rise worldwide as 
a consequence of demographic evolution even if age-
specific trend seems to be lower than previously expected.  
 
Understanding of cognitive 
ageing and dementia 
Dementia is a syndrome with multiple interacting causes, 
which can be clearly distinguished from healthy ageing. 
AD can be considered as a structural problem (specific 
atrophy with a decrease in synaptic connections in regions 
of the brain) coupled with a fall in cerebral metabolism.  
 
Biological causes of 
dementia 
Biological determinants of AD and dementia are complex. 
The anatomic sequence of neurofibrillary degeneration 
(tau pathology) is specific and reproducible, as opposed to 
the distribution of the amyloid burden. 
 
Detection and diagnosis of 
dementia 
Complete clinical neuropsychological assessment 
(comprehensive cognitive evaluation) is today the only 
way to make an accurate diagnosis of early neurocognitive 
disorder in AD or related diseases. Biomarkers remain 
reserved to research.  
 
New therapeutic targets for  
dementia 
A drug able to stop or reverse AD progression is not yet 
available.  
 
Psychosocial research and 
interventions in dementia 
Multi-component psychosocial interventions are effective 
in managing functional, behavioral and psychological 
symptoms of dementia. 
 
Assistive technology and 
dementia 
 ICTs can provide useful information for assisting older 
adults and also for assessing specific domains of AD 
patient’s life (behaviour, cognition, activities of daily 
living). Assistive technology must be specifically tailored 
to the end-user’s capacities. 
 
Sensory impairment and 
dementia 
There is some evidence for an association (not a causality) 
between sensory impairment and dementia. Non-corrected 
vision and hearing loss are associated with an increased 
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risk of incident dementia. Delirium, brain's failure to 
assimilate and respond appropriately to inner and outer 
stimuli, is a very strong risk factor for dementia in the 
oldest-old. 
 
Biomedical ethics and 
dementia 
A person-centred approach is essential for the well-being 
of people with dementia. The disability framework model 
creates an opportunity to understand better the importance 
of psychosocial interventions and of societal changes 
aimed at social participation. 
 
Dementia care Behavioural and psychological symptoms of dementia 
(BPSD), major determinants of caregiver burden, relate to 
unmet needs of people with dementia, mostly pain and 
discomfort, need of social contact and support, and need 
of stimulation against boredom. Non-pharmacological 
interventions are recommended as first-line therapy for 
BPSD. Agitated behavior responds to pain management.  
 
Public policies, economics 
and dementia 
Early diagnosis and early interventions are priorities. 
Policy focuses on spending now to save in the long term. 
Diagnosis and treatment became a right. Dementia is very 
expensive, with high costs stemming from the cost of care. 






Table 2: What is unknown? 
 





The individual course of dementia is hardly predictable. 
Cognitive and functional frailty coexist, depending upon the 
capacities of the impaired persons and their living 
ecosystem. 
 
Epidemiology, risk factors 
and prevention 
 
There are no data for prevalence, incidence and life 
expectancy using the new criteria for AD definition. Data on 
efficacy of large ongoing preventive trials and adherence of 
elders in long-term prevention strategies are awaited. 
Interventions based on the management of vascular and 
lifestyle-related risk factors may help prevent up to a third of 
AD cases worldwide. 
 
Understanding of cognitive 
ageing and dementia 
 
The role of different risk and protective factors can be 
clarified using a life-course perspective to describe the 
complex and dynamic interactions between factors in 
determining age-associated neurodegeneration. 
 
Biological causes of 
dementia 
 
Molecular mechanisms of AD and dementia are still largely 
unknown. Links between amyloid and tau pathologies are 
still ill-defined. The exact role of susceptibility genes in 
complex biological regulation pathways remains elusive. 
 
Detection and diagnosis  There are no simple tests for AD or dementia. The predictive 
value of biomarkers is not high enough to allow their use in 
screening. It may remain so in the next ten years.  
 
New therapeutic targets The aetiology and pathophysiology of AD are not fully 
known, making it difficult to identify proper targets and 
develop an effective cure. We do not know when a disease-
modifying drug for AD will be available. 
 
Psychosocial research and 
interventions in dementia 
Research is needed to understand the most efficient 
procedures for psychosocial intervention, the mechanisms of 
efficacy of the interventions and the modulating factors. 
Cultural, social and economic aspects of caregiving deserve 
more attention.  
 
Assistive technology in 
dementia 
More efforts in performance and evaluation of ICTs are 
needed to help industry meet user needs and general 
practitioners in prescribing the available technologies. A 
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solid economic model is a major issue for assistive 
technology development in dementia. 
 
Dementia and sensory 
impairment 
Sensory impairments may be either causal factors or 
consequences of dementia. Whether sensory impairments 
could be markers or modifiable risk factors for dementia 
remains debated. 
 
Biomedical ethics and 
dementia 
Research in nursing homes, clinical trials for complex cases, 
context analysis in technology implementation and effects of 
cultural differences on attitudes and practices about 
dementia deserve more attention. 
 
Dementia care The care system itself may produce adverse events in 
dementia care. Stemming from care needs, a logical, systems 
approach of the care environment through organizational, 
architectural and psychosocial interventions needs to be 
developed. 
 
Public policies, economics 
and dementia 
Direct measurements of cost and effectiveness of 
interventions are scarce. The best models of care are poorly 
diffused and implemented. There are no comprehensive 





Table 3: What are plausible directions for the future? 
 




It is important to discuss preserving the capacities of the 
cognitively impaired persons in their living ecosystem, 
rather than the sole biological aspects of the disease. A 
disability model, considering impairments in body 
functions and structures, limitations in individual 
activity and restrictions in social participations, is 
useful. 
 




A large cooperative prevention initiative has been set up 
in Europe. Effective policies at a State level may include 
individual and collective prevention, as well as policies 
towards agro-business companies and health insurance 
to change consumer behaviours such as those towards 
lipid-rich food. Better prevention may be more valuable 
than finding too many therapeutic targets, since AD is 
not a pure entity. 
 
Understanding of cognitive 
ageing and dementia 
Studies on biomarker validation will provide researchers 
with a better understanding of AD progression in its 
earliest stages.  
 
Biological causes of dementia There is a huge overlap among neurodegenerative 
disorders, with some common mechanisms. Better 
cross-linking of animal and human studies in 
neurodegenerative diseases should be encouraged. 
 
Detection and diagnosis of 
dementia 
An early diagnosis may be of interest for earlier clinical 
trials. Prognostic markers, rather than diagnostic ones, 
may prove more useful. Task-free MRI and task-based 
MRI may prove useful as non-invasive biomarkers in 
studying the progression of memory failure over the 
course of AD.  
 
New therapeutic targets Drugs are being tested at the pre-symptomatic phase, 
through the selection of subjects with genetic risk of 
familial AD or evidence of brain amyloid burden. New 
therapeutic approaches include compounds regulating 
brain response to insulin and neuroinflammation. 
 
Psychosocial research and 
interventions in dementia 
New methodological approaches associating 
quantitative and qualitative evaluation should be 
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encouraged, as well as research in nursing homes. Early 
psychosocial intervention at home should be developed, 
based on an individual model of patients’ needs, support 
and modulating factors. Stimulation approaches should 
be expanded to match the full range of cognitive 
impairments and sensory impairments. 
 
Assistive technology and 
dementia 
Serious games, with the notion of pleasurable activities 
and person empowerment, may structure collaborative 
care knowledge related to AD and educate AD 
stakeholders cope with critical situations in patient 
everyday life. 
 
Dementia and sensory 
impairment 
Collaborative research between associations active in 
sensory impairment and those active in dementia care, 
may bring new insight, with a double disability 
approach. Correcting vision and hearing loss may help 
reduce cognitive impairment. Reorientation and 
environmental stimulation may reduce delirium in the 
hospitalized elderly. 
 
Biomedical ethics and dementia Communication about AD research (funding and 
results) deserves more care, as it can reinforce stigma 
and give unrealistic hopes. 
 
Dementia care “Successful dementia” involves a shared understanding 
of non-pharmacological intervention in care services. 
Tailoring, dementia-friendly environments, culture and 
domesticity are key factors for such interventions. 
Research in dementia care, through coordinated, flexible 
research networks, involving field and university 
professionals, could become a marker of quality for 
innovative nursing homes. 
 
Public policies, economics and 
dementia 
The number of countries having implemented a National 
Dementia Strategy is expanding. WHO recognition of 
dementia as public health priority raises worldwide 
attention. Further developments in economics of 
dementia may increase political will and focus. 
 
 
 
